Beneficial plasma exchange response in central nervous system inflammatory demyelination

Archives of Neurology

Volumn 68, Issue 7, 2011, Pages 870-878

  Magaña, Setty M ^a   Keegan, B Mark ^a   Weinshenker, Brian G ^a   Erickson, Bradley J ^a   Pittock, Sean J ^a   Lennon, Vanda A ^a,b   Rodriguez, Moses ^a   Thomsen, Kristine ^a   Weigand, Stephen ^a   Mandrekar, Jay ^a   Linbo, Linda ^a   Lucchinetti, Claudia F ^a  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM INFLAMMATORY DEMYELINATING DISEASE; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE DURATION; DISEASE RESISTANCE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCORING SYSTEM; SEROLOGY; TENDON REFLEX; TREATMENT RESPONSE; UNITED STATES;

ADOLESCENT; ADULT; AGED; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; COHORT STUDIES; CONFIDENCE INTERVALS; DEMYELINATING DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ODDS RATIO; PLASMA EXCHANGE; SPINAL CORD; YOUNG ADULT;

EID: 79960186525     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.34     Document Type: Article

References (31)

1. Rodriguez M, Karnes WE, Bartleson JD, Pineda AA. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology. 1993;43(6):1100-1104. (Pubitemid 23177705)
2. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46(6):878-886.
3. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002;58(1):143-146.
4. Bennetto L, Totham A, Healy P, Massey E, Scolding N. Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system: a report of six cases. J Neurol. 2004;251(12):1515-1521. (Pubitemid 40169477)
5. Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007; 13(1):128-132. (Pubitemid 46152772)
6. Watanabe S, Nakashima I, Miyazawa I, et al. Successful treatment of a hypothalamic lesion in neuromyelitis optica by plasma exchange. J Neurol. 2007;254 (5):670-671. (Pubitemid 46781965)
7. Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler. 2009;15(4):487-492.
8. Mao-Draayer Y, Braff S, Pendlebury W, Panitch H. Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology. 2002;59(7):1074-1077.
9. Paus S, Prömse A, Schmidt S, Klockgether T. Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology. 2003;61 (7):1022. (Pubitemid 37248678)
10. Llufriu S, Castillo J, Blanco Y, et al. Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology. 2009;73 (12):949-953.
11. Dau PC. Plasmapheresis in acute multiple sclerosis: rationale and results. J Clin Apher. 1991;6(4):200-204.
12. Khatri BO. Therapeutic apheresis in neurological disorders. Ther Apher. 1999;3 (2):161-171. (Pubitemid 29242683)
13. Gold R, Hartung HP. Towards individualised multiple-sclerosis therapy. Lancet Neurol. 2005;4(11):693-694. (Pubitemid 41457283)
14. Archelos JJ, Storch MK, Hartung HP. The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol. 2000;47(6):694-706. (Pubitemid 30390190)
15. Keegan M, König F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 2005;366(9485):579-582. (Pubitemid 41140333)
16. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125(pt 7): 1450-1461. (Pubitemid 34755161)
17. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364 (9451):2106-2112. (Pubitemid 39626806)
18. Lublin FD, Reingold SC; National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4):907-911.
19. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227-231. (Pubitemid 13158528)
20. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127.
21. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-815. (Pubitemid 47238676)
22. Wingerchuk DM, Lucchinetti CF. Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol. 2007;20(3):343-350. (Pubitemid 46743119)
23. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499-505.
24. Tintoré M, Rovira A, Mart?́nez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol. 2000;21(4):702-706. (Pubitemid 30210434)
25. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997; 120(pt 11):2059-2069. (Pubitemid 27493740)
26. O'Brien PC. The appropriateness of analysis of variance and multiplecomparison procedures. Biometrics. 1983;39(3):787-794.
27. Perneger TV. What's wrong with Bonferroni adjustments. BMJ. 1998;316(7139): 1236-1238. (Pubitemid 28171344)
28. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43-46. (Pubitemid 20255621)
29. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
30. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444-1452. (Pubitemid 14237132)
31. Amiry-Moghaddam M, Ottersen OP. The molecular basis of water transport in the brain. Nat Rev Neurosci. 2003;4(12):991-1001. (Pubitemid 37486675)